Medical Business Review
Anonymous User | Login

Luxottica, Essilor Form JV For ANZ

Published: 08-Feb-2010

Luxottica Group (Luxottica) and Essilor International (Essilor) have formed a long-term joint-venture (JV) for the Australia and New-Zealand (ANZ) markets.

As per the agreement, the JV will manage Eyebiz, Luxottica’s Sydney-based optical lens finishing laboratory, which, as a result of this alliance, will be majority-controlled by Essilor.

Eyebiz expects to continue to supply all of Luxottica’s retail optical outlets in Australia and New Zealand. The Eyebiz management team is likely to remain in place and report to the new Board comprised of Essilor and Luxottica representatives.

Essilor International is engaged in the business of ophthalmic optical products, offering a range of lenses under the Varilux, Crizal, Essilor, Definity and Xperio brands, to correct myopia, hyperopia, astigmatism and presbyopia. Essilor operates worldwide through a network of mass-production facilities, lens finishing laboratories and local distribution subsidiaries.

Luxottica Group has over 6,200 optical and sun retail stores in North America, Asia-Pacific, China, South Africa and Europe. Group’s products are designed and manufactured in six Italy-based manufacturing plants, two wholly-owned plants in China and a sports sunglass production facility in the US.

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

WebWise Learning

Turning Information into Working Knowledge ...

Warwick Design Consultants

The Warwick Design team comprises skilled and experienced designers, engaged in the creation and dev...

Veldlaser Innovations

Laser Micromachining ...

UTC

UTC advanced technology and proprietary manufacturing processes produce urethane systems that contri...

TNO

Pharma Services: From Discovery to the Clinic ...

Thomson Reuters

The World's Leading Source of Life Sciences Intelligent Information ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Welcome to Berne Capital Area - Place for Business, Science and Living

Informative presentation on the Berne Capital Area, Switzerland ...

TNO Pharma Services: From Discovery to the Clinic

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Titanium Nitride (TiN)

Free white paper fact sheet on Tecvac's Titanium Nitride (TiN) product. ...

Stimulus Spending Brings Medical Application to Life: Opportunities and Challenges in Digital Records

Governments worldwide are pouring billions of dollars into health information technology. ...

Skin-Friendly Silicone

Advance wound care products represent a $4.9 billion global market and competition in this ...

Skin Care and Wound Management

Silicones have long been recognised as biocompatible and effective materials for a variety ...

Related Companies

Bausch & Lomb Incorporated

Bausch & Lomb Incorporated (Bausch & Lomb) is a eye health company, engaged in manufact ...

Essilor International

Essilor International (Essilor) is a leading producer of optical products. The company ...

Hoya Corporation

Hoya Corporation (Hoya) is one of the leading suppliers of innovative and indispensable ...

STAAR Surgical Company

STAAR Surgical Company (STAAR Surgical) is engaged in the development, manufacture and ...

Luxottica Group S.p.A.

Luxottica Group S.p.A. (Luxottica) is engaged in the design, manufacture and distributi ...

Suppliers Product News

Amarna Therapeutics B.V. and TNO Announce SVac Research and Development Partnership

Dutch biotechnology company Amarna Therapeutics B.V. and the Netherlands Organisation for Applied Scientific Research TNO today announced that they have entered into a collaboration agreement to further develop Amarna's viral gene delivery platform SVac.

Accovion Selects Liquent Insight Publisher

Contract Research Organization Chooses Thomson Reuters Software Solution

Thomson Reuters Makes Disease Briefing on Influenza Covering H1N1 (Swine Flu) Publicly Available

Free Access Given to Support the Global R&D and Healthcare Community

Thomson Reuters Announces the Availabilty of Three Pharma Matters Reports Covering January - March 2009

Quarterly Reports Use Market Intelligence and Competitive Analysis from Thomson Reuters to Highlight Developments in the Global Pharmaceutical Industry

Free Newsletter Sign-up

Sign up, and we will send you a free Medical report on Cell Therapy – A New Lease of Life for the Heart’ from GlobalData worth $750

Please enter a valid email address